Eli Lilly has announced the extension of the expiration of its tender offer to acquire all of the issued and outstanding shares of Point Biopharma Global common stock, for a purchase price of $12.50 per share in cash.

The tender offer, which was due to expire on November 16, 2023 at 5:00 p.m., has been extended to December 1, 2023 at 5:00 p.m., unless the tender offer is extended or terminated earlier, in order for the parties to satisfy the minimum tender condition.

All regulatory approvals required to complete the transaction have been obtained.

Copyright (c) 2023 CercleFinance.com. All rights reserved.